# US 2021/0198247 A1 · Indoleamine-2,3-dioxygenase inhibitor, the preparative method and the use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198247 A1
- Document ID: US20210198247A1
- Status: Published application
- Kind: A1
- Application number: 16/956,581
- Filed: 2018-12-20
- Published: 2021-07-01
- Earliest claimed: 2017-12-20
- Assignees: Hinova Pharmaceuticals Inc.
- Applicants: Hinova Pharmaceuticals Inc.
- Inventors: Wu DU; Chaowu AI; Yu LI; Kun WEN; Haibin LV; Wen REN; Jinyun HE; Dekun QIN; Xinghai LI; Yuanwei CHEN
- Web page: https://patentgrep.com/patent/US20210198247A1

## CPC

- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/12: for cataracts
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07D 413/14: containing three or more hetero rings
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Provided is a compound represented by formula (I). Also provided are a pharmaceutical composition containing the compound of formula (I) and use of the compound in preparing indoleamine-2,3-dioxygenase (IDO) inhibitor drugs. The compound or the pharmaceutical composition thereof can be used for preparing drugs for preventing and/or treating diseases having pathological features of IDO-mediated tryptophan metabolic pathways.

## Claims

### Claim 1

Compounds of formula (I), or optical isomers thereof, or cis- and trans-isomers thereof, or solvates thereof, or pharmaceutically acceptable salts thereof, or pro-drugs thereof, or tautomers thereof, or mesomers thereof, or racemates thereof, or enantiomers thereof, or diastereoisomers thereof, or mixtures thereof, or metabolites thereof, or metabolic precursors thereof:
Wherein, X is amino group, oxygen and sulfur;
R1 is hydrogen, —(CH2)mCOR5, —(CH2)mSO2R6, —(CH2)mCOOR7, alkyl, haloalkyl, alkoxy, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, unsaturated heterocyclic group, substituted unsaturated heterocycloalkyl, aryl, substituted aryl, aromatic heterocyclic group, and substituted heteroaryl; m is selected from integers of 0-5;
R5, R6 and R7 are independently of each other selected from alkyl, amino, —NR8R9, hydroxy, cycloalkyl, alkoxy, heterocycloalkyl, —CONR8R9, aryl, and aromatic heterocyclic group;
R8 and R9 are independently of each other selected from hydrogen, amino, hydroxy, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or
R8 and R9 are linked together to form a ring;
R2 is hydrogen, alkyl, hydroxyl, amino, alkoxy, alkylamino, and halogen;
R3 and R4 are respectively selected from hydrogen, halogen, cyano, alkyl, cycloalkyl, heterocycloalkyl, alkoxy, amino, carboxyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
Wherein, hydrogen means hydrogen element (H) or isotope deuterium (D);
a is an integer of 0 to 5; b is an integer of 0 to 5; c is an integer of 1 to 5; a and b are not both 0.

### Claim 2 (depends on 1)

Said compounds, or optical isomers thereof, or cis- and trans-isomers thereof, or solvates thereof, or pharmaceutically acceptable salts thereof, or pro-drugs thereof, or tautomers thereof, or mesomers thereof, or racemates thereof, or enantiomers thereof, or diastereoisomers thereof, or mixtures thereof, or metabolites thereof, or metabolic precursors thereof according to claim 1, characterized in that said compounds have a structure of formula (II):
R6 is selected from the group consisting of alkyl, amino, hydroxy, cycloalkyl, alkoxy, heterocycloalkyl, —CONR8R9, —NR8R9, aryl, and aromatic heterocyclic group;
R8 and R9 are independently of each other selected from hydrogen, amino, hydroxy, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or
R8 and R9 are linked together to form a ring.

### Claim 3 (depends on 1)

Said compounds, or optical isomers thereof, or cis- and trans-isomers thereof, or solvates thereof, or pharmaceutically acceptable salts thereof, or pro-drugs thereof, or tautomers thereof, or mesomers thereof, or racemates thereof, or enantiomers thereof, or diastereoisomers thereof, or mixtures thereof, or metabolites thereof, or metabolic precursors thereof according to claim 1, characterized in that said compounds have a structure of formula (III):
Wherein, R5 is selected from the group consisting of alkyl, amino, hydroxy, cycloalkyl, alkoxy, heterocycloalkyl, —CONR8R9, —NR8R9, aryl, and aromatic heterocyclic group;
R8 and R9 are independently of each other selected from hydrogen, amino, hydroxy, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or
R8 and R9 are linked together to form a ring.

### Claim 4 (depends on 1)

Said compounds, or optical isomers thereof, or cis- and trans-isomers thereof, or solvates thereof, or pharmaceutically acceptable salts thereof, or pro-drugs thereof, or tautomers thereof, or mesomers thereof, or racemates thereof, or enantiomers thereof, or diastereoisomers thereof, or mixtures thereof, or metabolites thereof, or metabolic precursors thereof according to claim 1, characterized in that when a is 0, said compounds have a structure of formula (IV);
when b is 0, said compounds have a structure of formula (V):
R1 is hydrogen, COR5, SO2R6, C1-C8 alkyl, C1-C8 haloalkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, C3-C8 unsaturated heterocyclic group, aryl, substituted aryl, aromatic heterocyclic group, and substituted heteroaryl;
R5 and R6 are dependently of each other selected from the group consisting of alkyl, hydroxy, C3-C8 cycloalkyl, alkoxy, C3-C8 heterocycloalkyl, —CONR8R9, —NR8R9, aryl, and heteroaryl;
R8 and R9 are independently of each other selected from hydrogen, amino, hydroxy, C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or R1 and R9 are linked together to form a ring;
R2 is hydrogen, C1-C8 alkyl, hydroxyl, amino, C1-C8 alkoxy, C1-C8 alkylamino, and halogen;
R3 and R4 are respectively selected from hydrogen, halogen, C1-C8 alkyl, C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, C1-C8 alkoxy, amino, carboxyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

### Claim 5 (depends on 1)

Said compounds, or optical isomers thereof, or cis- and trans-isomers thereof, or solvates thereof, or pharmaceutically acceptable salts thereof, or pro-drugs thereof, or tautomers thereof, or mesomers thereof, or racemates thereof, or enantiomers thereof, or diastereoisomers thereof, or mixtures thereof, or metabolites thereof, or metabolic precursors thereof according to claim 1, characterized in that when a is 1 and b is 1, said compounds have a structure of formula (VI):
R1 is hydrogen, COR5, SO2R6, C1-C8 alkyl, C1-C8 haloalkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, C3-C8 unsaturated heterocyclic group, aryl, substituted aryl, aromatic heterocyclic group, and substituted heteroaryl;
R5 and R6 are dependently of each other selected from the group consisting of alkyl, hydroxy, C3-C8 cycloalkyl, alkoxy, C3-C8 heterocycloalkyl, —CONR8R9, —NR8R9, aryl, and heteroaryl;
R8 and R9 are independently of each other selected from hydrogen, amino, hydroxy, C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or R1 and R9 are linked together to form a ring;
R2 is hydrogen, C1-C8 alkyl, hydroxyl, amino, C1-C8 alkoxy, C1-C8 alkylamino, and halogen;
R3 and R4 are respectively selected from hydrogen, halogen, C1-C8 alkyl, C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, C1-C8 alkoxy, amino, carboxyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

### Claim 6 (depends on 1)

Said compounds, or optical isomers thereof, or cis- and trans-isomers thereof, or solvates thereof, or pharmaceutically acceptable salts thereof, or pro-drugs thereof, or tautomers thereof, or mesomers thereof, or racemates thereof, or enantiomers thereof, or diastereoisomers thereof, or mixtures thereof, or metabolites thereof, or metabolic precursors thereof according to claim 1, characterized in that said compounds include following compounds, but not limited to these compounds:

### Claim 7 (depends on 1)

The use of said compounds, or optical isomers thereof, or cis- and trans-isomers thereof, or solvates thereof, or pharmaceutically acceptable salts thereof, or pro-drugs thereof, or tautomers thereof, or mesomers thereof, or racemates thereof, or enantiomers thereof, or diastereoisomers thereof, or mixtures thereof, or metabolites thereof, or metabolic precursors thereof according to claim 1 in the preparation of drugs for the prevention and/or treatment of diseases with pathological characteristics of IDO mediated tryptophan metabolism pathway.

### Claim 8 (depends on 1)

The use of said compounds, or optical isomers thereof, or cis- and trans-isomers thereof, or solvates thereof, or pharmaceutically acceptable salts thereof, or pro-drugs thereof, or tautomers thereof, or mesomers thereof, or racemates thereof, or enantiomers thereof, or diastereoisomers thereof, or mixtures thereof, or metabolites thereof, or metabolic precursors thereof according to claim 1 in the preparation of IDO inhibitors.

### Claim 9 (depends on 7)

The use according to claim 7, characterized in that said drugs are used for treatment of cancer, myelodysplastic syndrome, Alzheimer's disease, autoimmune disease, depression, anxiety disorder, cataract, psychological disorder and AIDS; in which said cancer is preferably breast cancer, cervical cancer, colon cancer, lung cancer, gastric cancer, rectal cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, prostate cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumor, ovarian tumor, peritoneal tumor, stage IV melanoma, solid tumor, glioma, neuroglioblastoma, hepatocyte cancer, and mastoid nephroma.

### Claim 10 (depends on 1)

A drug combination, characterized in that said drug combination is a formulation prepared by using said compounds, or optical isomers thereof, or cis- and trans-isomers thereof, or solvates thereof, or pharmaceutically acceptable salts thereof, or pro-drugs thereof, or tautomers thereof, or mesomers thereof, or racemates thereof, or enantiomers thereof, or diastereoisomers thereof, or mixtures thereof, or metabolites thereof, or metabolic precursors thereof according to claim 1 as active ingredients, with the addition of pharmaceutically acceptable excipients.
